자료유형 | E-Book |
---|---|
단체저자명 | International Commission on the Clinical Use of Human Germline Genome Editing,issuing body. |
서명/저자사항 | Heritable human genome editing /International Commission on the Clinical Use of Human Germline Genome Editing ; National Academy of Medicine ; National Academy of Sciences ; and the Royal Society.[electronic resource] |
발행사항 | Washington, DC : The National Academies Press, [2020] |
형태사항 | 1 online resource (1 PDF file (xviii, 219 pages)) : color illustrations. |
총서사항 | Consensus study report |
소장본 주기 | Master record variable field(s) change: 050, 082 |
ISBN | 9780309671163 0309671167 |
서지주기 | Includes bibliographical references. |
내용주기 | Intro -- FrontMatter -- Special Acknowledgments -- Foreword -- Contents -- Boxes and Figures -- Summary -- 1 Introduction -- 2 The State of the Science -- 3 Potential Applications of Heritable Human Genome Editing -- 4 A Translational Pathway to Limited and Controlled Clinical Applications of Heritable Human Genome Editing -- 5 National and International Governance of Heritable Human Genome Editing -- References -- Appendix A: Information Sources and Methods -- Appendix B: Commissioner Biographies -- Appendix C: Glossary -- Appendix D: Acronyms and Abbreviations -- Acknowledgment of Reviewers |
요약 | "Heritable human genome editing - making changes to the genetic material of eggs, sperm, or any cells that lead to their development, including the cells of early embryos, and establishing a pregnancy - raises not only scientific and medical considerations but also a host of ethical, moral, and societal issues. Human embryos whose genomes have been edited should not be used to create a pregnancy until it is established that precise genomic changes can be made reliably and without introducing undesired changes - criteria that have not yet been met, says Heritable Human Genome Editing. From an international commission of the U.S. National Academy of Medicine, U.S. National Academy of Sciences, and the U.K.'s Royal Society, the report considers potential benefits, harms, and uncertainties associated with genome editing technologies and defines a translational pathway from rigorous preclinical research to initial clinical uses, should a country decide to permit such uses. The report specifies stringent preclinical and clinical requirements for establishing safety and efficacy, and for undertaking long-term monitoring of outcomes. Extensive national and international dialogue is needed before any country decides whether to permit clinical use of this technology, according to the report, which identifies essential elements of national and international scientific governance and oversight."-- |
기금정보주기 | This activity was supported by Contract No. HHSN263201800029I / Order No. 75N98019F00852 from the U.S. National Institutes of Health, Grant No. 2019 HTH 009 from the Rockefeller Foundation, and Grant 218375/Z/19/Z from the Wellcome Trust, with additional support from the Royal Society of the United Kingdom, the Cicerone Endowment Fund of the U.S. National Academy of Sciences, and the NAM Initiatives Fund of the U.S. National Academy of Medicine. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. |
일반주제명 | Human genome. Gene editing. Ethics. Gene Editing. Genome. Quantitative Trait, Heritable. Genomics -- methods. Ethics. Gene editing. Human genome. |
언어 | 영어 |
기타형태 저록 | Print version:Society, The RoyalHeritable Human Genome EditingWashington, D.C. : National Academies Press,c20219780309671132 |
대출바로가기 | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=2742053 |
인쇄
No. | 등록번호 | 청구기호 | 소장처 | 도서상태 | 반납예정일 | 예약 | 서비스 | 매체정보 |
---|---|---|---|---|---|---|---|---|
1 | WE00019534 | 572.86 | 가야대학교/전자책서버(컴퓨터서버)/ | 대출가능 |